{
    "nct_id": "NCT03440385",
    "official_title": "Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease",
    "inclusion_criteria": "* Crohn's disease for ≥ 3 months on endoscopy and on histological exam\n* Inadequate response or loss of response to corticosteroids, immunomodulators, and/or biologic therapy\n* Crohn's Disease Activity Index (CDAI) score ≥ 220 and ≤ 450\n* Average daily stool frequency ≥ 4 points and/or an abdominal pain of ≥ 2 points\n* Simple Endoscopic Score for Crohn's Disease (SES-CD) score of ≥ 6 (or SES-CD ≥ 4 in participants with isolated ileal disease)\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Diagnosis of ulcerative colitis, indeterminate colitis, radiation colitis, or ischemic colitis, or has strictures with prestenotic dilatation requiring procedural intervention\n* Extensive small bowel resection (>100cm) or known diagnosis of short bowel syndrome, or requires total parenteral nutrition\n* Current stoma, ileal-anal pouch anastomosis, or fistula\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com"
}